RAPT Therapeutics, Inc. (RAPT)

NASDAQ: RAPT · IEX Real-Time Price · USD
8.72
-0.52 (-5.63%)
At close: Feb 23, 2024, 4:00 PM
8.88
+0.16 (1.83%)
After-hours: Feb 23, 2024, 7:56 PM EST
-5.63%
Market Cap 299.93M
Revenue (ttm) n/a
Net Income (ttm) -108.87M
Shares Out 34.40M
EPS (ttm) -2.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,390,215
Open 9.15
Previous Close 9.24
Day's Range 8.63 - 9.50
52-Week Range 6.86 - 31.45
Beta 0.66
Analysts Buy
Price Target 25.44 (+191.74%)
Earnings Date Mar 12, 2024

About RAPT

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 31, 2019
Employees 129
Stock Exchange NASDAQ
Ticker Symbol RAPT
Full Company Profile

Financial Performance

In 2022, RAPT's revenue was $1.53 million, a decrease of -59.95% compared to the previous year's $3.81 million. Losses were -$83.84 million, 21.1% more than in 2021.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for RAPT stock is "Buy." The 12-month stock price forecast is $25.44, which is an increase of 191.74% from the latest price.

Price Target
$25.44
(191.74% upside)
Analyst Consensus: Buy
Stock Forecasts

News

RAPT Therapeutics' stock plunges as FDA halts two clinical trials

RAPT Therapeutics Inc. shares RAPT, +1.68% dropped more than 60% premarket on Tuesday after the company said regulators have hit pause on two clinical trials of its experimental inflammation treatment...

5 days ago - Market Watch

FDA puts on hold two Rapt Therapeutics mid-stage drug trials

Rapt Therapeutics said on Tuesday the U.S. FDA had placed on hold two mid-stage trials of the company's drug to treat eczema and asthma, after liver failure was observed in one of the patients.

5 days ago - Reuters

RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

- RAPT to host a conference call today at 8:30 am ET - SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biophar...

5 days ago - GlobeNewsWire

RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and co...

12 days ago - GlobeNewsWire

RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and co...

25 days ago - GlobeNewsWire

RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and co...

7 weeks ago - GlobeNewsWire

RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

SOUTH SAN FRANCISCO, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing a...

3 months ago - GlobeNewsWire

RAPT Therapeutics Reports Third Quarter 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and co...

3 months ago - GlobeNewsWire

RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

- Confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥ 1%) patients with no prior checkpoint inhibitor therapy (CPI)

4 months ago - GlobeNewsWire

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and co...

4 months ago - GlobeNewsWire

RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and co...

4 months ago - GlobeNewsWire

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and co...

6 months ago - GlobeNewsWire

RAPT Therapeutics Reports Second Quarter 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and co...

7 months ago - GlobeNewsWire

RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and co...

9 months ago - GlobeNewsWire

RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers

-FLX475-treated patients exhibited significant changes in immune pathways likely to enhance an antitumor response -FLX475 modifies the tumor microenvironment (TME) to resemble those of responders to a...

9 months ago - GlobeNewsWire

RAPT Therapeutics Reports First Quarter 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and com...

10 months ago - GlobeNewsWire

RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel

SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and com...

10 months ago - GlobeNewsWire

RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and c...

10 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

NEW YORK , April 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT). Such investors are advised to...

11 months ago - PRNewsWire

RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma

SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and c...

11 months ago - GlobeNewsWire

RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results

Company maintains strong cash position of $249.1 million Company maintains strong cash position of $249.1 million

1 year ago - GlobeNewsWire

RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing a...

1 year ago - GlobeNewsWire

RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing a...

1 year ago - GlobeNewsWire

RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer

Data Presented at ESMO Immuno-Oncology Congress Data Presented at ESMO Immuno-Oncology Congress

1 year ago - GlobeNewsWire

RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage, immunology-based biopharmaceutical company focused on...

1 year ago - GlobeNewsWire